Showing results (1181-1190 of 2,664) with videos related to

Sort By:
Pageof 267
Clinical & Experimental Ophthalmology|December 6, 2013
Mitomycin C versus 5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trialsLígia I De Fendi, Gustavo V Arruda, Ingrid U Scott, et al.
Clinical & Experimental Ophthalmology|December 13, 2012
Combining phacoemulsification with endoscopic cyclophotocoagulation to manage cataract and glaucomaColin I Clement, George Kampougeris, Faisal Ahmed, et al.
Clinical & Experimental Ophthalmology|January 3, 2013
Neuro-ophthalmology of invasive fungal sinusitis: 14 consecutive patients and a review of the literatureMatthew J Thurtell, Alison L S Chiu, Lucy A Goold, et al.
Clinical & Experimental Ophthalmology|January 3, 2013
Is preoperative ciliary body and iris anatomical configuration a predictor of malignant glaucoma development?Tiago S Prata, Syril Dorairaj, Carlos G V De Moraes, et al.
Clinical & Experimental Ophthalmology|August 10, 2013
Long-term visual outcomes in patients with orbitotemporal neurofibromatosisTimothy H Greenwell, Peter J Anderson, Simon K Madge, et al.
Clinical & Experimental Ophthalmology|August 10, 2013
Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasiaBobak Bahrami, Timothy Greenwell, James S Muecke
Clinical & Experimental Ophthalmology|October 12, 2013
Chromosome 9p21 primary open-angle glaucoma susceptibility locus: a reviewSoo Khai Ng, Robert J Casson, Kathryn P Burdon, et al.
Clinical & Experimental Ophthalmology|October 15, 2013
Nasolacrimal duct screening to minimize post-cataract surgery endophthalmitisJonathan K Kam, Nicholas M Cheng, Marc Sarossy, et al.
Clinical & Experimental Ophthalmology|April 23, 2013
Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitisZubeyde A Polat, Julia Walochnik, Andreas Obwaller, et al.
Clinical & Experimental Ophthalmology|June 20, 2013
Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexoneIan S Zagon, Joseph W Sassani, Jessica A Immonen, et al.
Pageof 267